GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 679, doi. 10.1007/s40263-023-01030-7
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2023 AND VI 37 AND IP 8
Results: 6
1
2
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 695, doi. 10.1007/s40263-023-01028-1
- By:
- Publication type:
- Article
3
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 715, doi. 10.1007/s40263-023-01026-3
- By:
- Publication type:
- Article
4
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 725, doi. 10.1007/s40263-023-01024-5
- By:
- Publication type:
- Article
5
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 671, doi. 10.1007/s40263-023-01021-8
- By:
- Publication type:
- Article
6
The Utilization of Low Dose Naltrexone for Chronic Pain.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 663, doi. 10.1007/s40263-023-01018-3
- By:
- Publication type:
- Article